These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 28774852)
1. Enhanced efficacy of anti-miR-191 delivery through stearylamine liposome formulation for the treatment of breast cancer cells. Sharma S; Rajendran V; Kulshreshtha R; Ghosh PC Int J Pharm; 2017 Sep; 530(1-2):387-400. PubMed ID: 28774852 [TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. Zhang W; Peng F; Zhou T; Huang Y; Zhang L; Ye P; Lu M; Yang G; Gai Y; Yang T; Ma X; Xiang G Int J Nanomedicine; 2015; 10():4825-36. PubMed ID: 26251599 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer. Kardani A; Yaghoobi H; Alibakhshi A; Khatami M J Cell Physiol; 2020 Oct; 235(10):6887-6895. PubMed ID: 32003016 [TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858 [TBL] [Abstract][Full Text] [Related]
5. Improved delivery of miR-1296 loaded cationic nanoliposomes for effective suppression of triple negative breast cancer. Albakr L; Alqahtani FY; Aleanizy FS; Alomrani A; Badran M; Alhindas H; Al-Mohanna F Saudi Pharm J; 2021 May; 29(5):446-455. PubMed ID: 34135670 [TBL] [Abstract][Full Text] [Related]
6. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells. Devulapally R; Sekar TV; Paulmurugan R Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495 [TBL] [Abstract][Full Text] [Related]
7. Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo. He K; Liu J; Gao Y; Hao Y; Yang X; Huang G AAPS PharmSciTech; 2020 Jul; 21(5):193. PubMed ID: 32661922 [TBL] [Abstract][Full Text] [Related]
8. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367 [TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537 [TBL] [Abstract][Full Text] [Related]
10. Effects of cationic liposomes with stearylamine against virus infection. Tahara K; Kobayashi M; Yoshida S; Onodera R; Inoue N; Takeuchi H Int J Pharm; 2018 May; 543(1-2):311-317. PubMed ID: 29625169 [TBL] [Abstract][Full Text] [Related]
11. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480 [TBL] [Abstract][Full Text] [Related]
12. In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells. Kaban K; Salva E; Akbuga J Nucleic Acid Ther; 2017 Feb; 27(1):45-55. PubMed ID: 27763825 [TBL] [Abstract][Full Text] [Related]
13. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. Mullick Chowdhury S; Wang TY; Bachawal S; Devulapally R; Choe JW; Abou Elkacem L; Yakub BK; Wang DS; Tian L; Paulmurugan R; Willmann JK J Control Release; 2016 Sep; 238():272-280. PubMed ID: 27503707 [TBL] [Abstract][Full Text] [Related]
14. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702 [TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy. Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949 [TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Liu XQ; Song WJ; Sun TM; Zhang PZ; Wang J Mol Pharm; 2011 Feb; 8(1):250-9. PubMed ID: 21138272 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells. Lujan H; Griffin WC; Taube JH; Sayes CM Int J Nanomedicine; 2019; 14():5159-5173. PubMed ID: 31371954 [No Abstract] [Full Text] [Related]
18. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate. She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714 [TBL] [Abstract][Full Text] [Related]
20. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]